

WO 2004/089253 A1



GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW). Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PERCUTANEOUSLY DEPLOYED VASCULAR VALVES

5 REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of United States Patent Application No. 60/459,475 filed April 1, 2003, which is hereby incorporated herein by reference in its entirety.

10

BACKGROUND

[0001] The present invention resides generally in the field of medical devices, and more particularly relates to artificial valve devices such as those
15 implanted within the vascular system.

[0002] As further background, in all vertebrates, blood is transported away from the heart and throughout the body via arteries and returns to the heart through veins. To allow for optimal transport back to the
20 heart and to reduce blood pressure build-up, veins contain various valves within their lumens, which open to permit blood flow to the heart but close to prevent the backflow of blood. Accordingly, venous valves function to provide the unidirectional flow of blood
25 back to the heart.

[0003] Problems can arise when these venous valves fail to function properly. For example, venous valves can become incompetent or damaged by disease such that the backflow of blood is not prevented. When this
30 occurs, blood pressure builds up and the veins and their valves become dilated, particularly in the lower extremities. If enough pressure builds up, the condition of venous insufficiency may develop. The severity of this condition is substantial, resulting in

swelling, extensive pain, deformities, and, in the most severe cases, the development of ulcers can occur. If these ulcers become infected, amputation may ultimately be necessary to save the patient's life.

5 [0004] Currently, there is no proven cure for venous insufficiency. Basic treatments include elevation of the legs or the use of compression stockings. If surgery is determined to be necessary, vein stripping is typically performed, which involves the removal of
10 the incompetent or damaged vein(s). Other surgical methods involve valvular reconstruction or transplantation.

 [0005] Recently, the development of artificial and biological valves has been employed in an attempt to
15 return normal pressure to the veins. There are a variety of these valves described in the art, which are generally designed to allow normal flow of blood back to the heart, while preventing retrograde flow. For example, US Patent No. 6,508,833 discloses a multiple-
20 sided medical device comprising a closed frame of a single piece of wire or other resilient material and having a series of bends and interconnecting sides. The device has both a flat configuration and a second, folded configuration that comprises a self-expanding
25 frame. The device is pushed from a delivery catheter into the lumen of a duct or vessel. A covering of fabric or other flexible material is sutured or attached to the frame to form an artificial valve. The flexible material utilized in the disclosed valves can
30 be comprised of collagenous submucosa obtained from various animals, such as, for example, pigs, cattle,

and sheep. This material can be processed and preserved so as to be capable of inducing host tissue proliferation, remodeling, and regeneration of appropriate tissue structures e.g., veins upon
5 implantation in vivo (see, e.g., U.S. Patent No. 6,485,723). The preparation of submucosal material is generally described in U.S. Patent Nos. 4,902,508 and 5,554,389. The submucosal material can be prepared in large, flat sheets, which are subsequently cut and
10 attached to a framing element, for example a stent, for deployment in a vein.

[0006] Despite work in the area there remain needs for medical products and methods for grafting within the vasculature, including the venous system, to
15 improve blood flow. Desirably, such products and methods could eliminate or minimize the need for the presence of implanted support structures such as stents or frames, associated with the engrafted or implanted product. Such support structures commonly exert
20 significant radial force upon vessel walls, and in certain situations may migrate deleteriously into the walls and/or undesirably reduce the compliancy of the vessel in which they are implanted. As well, such stent or frame structures can present increased risks
25 for thrombosis or embolism.

SUMMARY

[0007] In one embodiment, the present invention provides a vascular valve that comprises a stentless vascular valve body having at least one flexible or otherwise movable member for restricting blood flow. The flexible member has an edge for engaging a wall of a vascular vessel. The valve also includes wall-engaging adaptations located along the edge. The wall-engaging adaptations can include any suitable devices or materials such as barbs, adhesives, or the like. In preferred devices, the stentless vascular valve body is made with a remodelable material and in particular a remodelable extracellular matrix material.

[0008] In another embodiment, the invention provides a percutaneous vascular valve and delivery system. This system includes a stentless vascular valve body having at least one flexible or otherwise movable member for restricting blood flow, the flexible member having an edge for engaging a wall of a vascular vessel. This system further includes a percutaneous deployment device, wherein the deployment device has an expandable element adapted to force the edge against the vessel wall. Suitable stentless vascular valve bodies are as described above. Suitable percutaneous deployment devices may include a balloon catheter having adaptations for selectively forcing the edge against the vessel wall, and/or elongate devices having at least one expandable frame attached thereto with adaptations for expanding and contracting the frame while remaining attached to the elongate device. The stentless valve body may be releasably attached to the

deployment device by any suitable means including by the use of adhesives or removable elements such as removable sutures.

[0009] The invention also provides a method for
5 treating venous insufficiency, wherein the method includes deploying a stentless vascular valve body such as that described above so as to force the valve body against the vascular wall, and selectively attach edges of the valve body against the vascular wall, to seat
10 the valve within the vein.

[0010] In another embodiment, the present invention provides a method for modifying blood flow in a vascular vessel. This method includes percutaneously delivering one or more pieces of flexible material to a
15 site within a vascular vessel. The method further includes percutaneously attaching at least portions of the one or more pieces of flexible material to walls of the vascular vessel, so as to form a structure that selectively permits blood flow at a first direction and
20 restricts blood flow in a second direction. Desirably, the flexible material in this embodiment will have remodelable properties, and may for example include an extracellular matrix material. In certain forms, the percutaneous attachment can be achieved by the delivery
25 of energy to facilitate attachment of the portions of the flexible material to the wall. For example, this energy may activate a substance to bond the flexible material to the wall, and/or may weld the material to the wall as occurs in tissue welding applications.

[0011] Additional embodiments as well as features and advantages of the invention will be apparent to those skilled in the art from the descriptions herein.

DESCRIPTION OF THE FIGURES

[0012] Figure 1 provides a perspective view of one valve device of the invention.

[0013] Figures 1a, 1b, and 1c illustrate various
5 configurations of attachments of barbs to valve devices.

[0014] Figure 2 provides a perspective view of another valve device of the invention.

[0015] Figure 3 provides a perspective view of one
10 illustrative percutaneous deployment device of the invention.

[0016] Figure 4 provides a perspective view of a vascular valve deployment system having a valve body received upon the deployment device of Figure 3.

15 [0017] Figure 5 provides a perspective view of another vascular valve deployment system of the invention.

[0018] Figure 6 provides a perspective view of another vascular valve deployment system of the
20 invention positioned within a vascular vessel.

[0019] Figure 7 provides a cut-away perspective view of a percutaneous valve material delivery device of the invention.

[0020] Figure 8 provides a cut-away perspective view
25 of one manner of securing a flexible material to the device of Figure 7.

[0021] Figure 9 provides a cross-sectional view taken along line 9-9 of Figure 8, after tucking the flexible material, and viewed in the direction of the arrows.

[0022] Figure 10 provides an illustration of the use of the system depicted in Figures 7 through 9 in use to provide a valve within a vascular vessel.

[0023] Figure 11 provides a top view of one
5 illustrative implanted valve of the invention.

[0024] Figure 12 provides a top view of another implanted valve of the invention.

[0025] Figure 13 provides a side view of an illustrative implanted valve of the invention.

DETAILED DESCRIPTION

[0026] For the purposes of promoting an understanding of the principles of the invention, reference will now be made to the embodiment illustrated in the drawings and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, and alterations and modifications in the illustrated device, and further applications of the principles of the invention as illustrated therein are herein contemplated as would normally occur to one skilled in the art to which the invention relates.

[0027] As disclosed above, the present invention provides vascular valve devices, and systems and methods for the delivery thereof.

[0028] With reference now to Figure 1, shown is a perspective view of an illustrative valve device 11 of the present invention. Device 11 includes a stentless or frameless valve body formed of a flexible material 12, wherein in the illustrated embodiment the valve body includes a first leaflet 13 and a second leaflet 14. It will be understood in this regard that valve bodies having one leaflet, or a plurality of leaflets, e.g. two, three, four, five or more leaflets, are contemplated as within the scope of the present invention.

[0029] The valve body of device 11 includes an opening 15, configured to facilitate the valve function by selectively allowing blood flow in a first direction, and selectively restricting blood flow in a second direction opposite the first direction. Device

11 in particular is designed to facilitate net blood flow in the direction of the arrow. Leaflets 13 and 14 are formed with a flexible material and move outwardly to open the opening 15 when subjected to blood flow in the direction of the arrow, and move inwardly to close the opening 15 when subjected to blood flow in a direction opposite that of the arrow.

[0030] Device 11 also includes a lip 16 or other reinforcement along the edges of the leaflets 13 and 14. This lip 16 may be made from the same material or a different material than that of the leaflets 13 and 14. For example, lip 16 may be made by folding, rolling, or otherwise gathering and securing material at the periphery of material from which leaflets 13 and 14 are made. Alternatively, a different material may be secured to the periphery of leaflets 13 and 14 to provide the lip or other reinforcement. Still further, leaflets 13 and 14 may be integrally made with a reinforced lip 16, for example by molding, and/or material at the periphery of leaflets 13 and 14 may be treated to increase its strength relative to the remainder of leaflets 13 and 14, for example by adding crosslinking to the periphery where leaflets 13 and 14 are made of collagenous materials.

[0031] Lip 16 in the illustrated device incorporates adaptations for attachment to the vessel wall. For example, lip 16 can include a plurality of elements configured to partially or completely penetrate the vessel walls, for example barbs or hooks. Alternatively or in addition, lip 16 can be provided with a biocompatible adhesive sufficient to secure lip

16 to the vessel wall. A range of biocompatible and potentially also biodegradable adhesives are known and can be used in the present invention for this purpose. Lip 16 can be provided with the adhesive in any
5 suitable manner, including for example a coating of adhesive on a surface of lip 16 that will come into contact with the vessel wall. As well, lip 16 can incorporate a sleeve or pocket (e.g. formed by folding back a portion of the material and attaching the edge
10 to form a sleeve), and the sleeve or pocket can contain a biocompatible adhesive that will be released through openings such as slits or apertures in the sleeve upon compressing the lip 16 against the surface of the vessel wall. In still further embodiments of the
15 invention, the adhesive can be applied *in situ* in the vessel the lip 16, and/or to corresponding areas of the vessel wall, using a catheter or other suitable delivery device.

[0032] With reference now to Figures 1A-1C, shown are
20 a number of ways to incorporate barbs into the lip 16 of the device 11. In Figure 1A, barbs are provided with a suturable base, and each base is secured with individual suture knots 19 within a fold created along stitch line 18. In Figure 1B, barbs are provided along
25 a wire element 20, with each barb having a base 21 spaced from the others along the wire element 20. This wire element can similarly be stitched underneath a fold at the edge of leaflets 13 and 14, with the barbs penetrating the material at the edge of the leaflets 13
30 and 14. It will be understood that in this disclosed embodiment, this wire element does not constitute a

stent, frame or other valve body support structure, as it does not serve to itself exert radial force upon the vessel walls to retain the position of the device, as would a stent. To the contrary, in certain
5 embodiments, wire element 20 can be highly maleable, taking on the configuration to which it is forced, while not having sufficient resiliency or integrity to maintain significant radial force against a vessel wall. In Figure 1C, each barb has a base 22 that is
10 individually bonded to the periphery of the leaflets 13 and 14, for example with a suitable biocompatible adhesive. Still other means for securing barbs or similar attachment elements to the device 11 will be apparent to those skilled in the art given the
15 teachings herein.

[0033] Referring now to Figure 2, shown is another embodiment of valve device 11, which is similar to that shown in Figure 1 except in respect of the attachment elements along the periphery of the leaflets. In
20 particular, Figure 2 shows device 11 having a multitude of small, closely spaced vessel-wall-penetrating elements such as hooks 24 along the periphery of the valve body. To facilitate attachment, the small hooks or other penetrating elements are provided in a regular
25 or irregular array along the lip of the device, particularly wherein the array includes hooks occurring generally longitudinally and laterally with respect to one another. That is, the array or swath of hooks or other elements along the periphery is desirably two or
30 more hooks or elements wide, and as well extends longitudinally along the periphery. Further in this

regard, it will be understood that the hooks or other penetrating elements such barbs can have a variety of sizes, orientations, and/or shapes. The individual elements can adopt a curved configuration and/or can
5 have adaptations to cause them to resist withdrawal from the wall tissue once inserted therein, e.g. in the case of fish hook-type structures. As well, the penetrating elements can be oriented in differing directions from one another, for example utilizing
10 multiple rows of either inward or outwardly facing barbs, or mixtures thereof. Such configurations for providing effective attachment to the walls, and resistance to withdrawal or migration, are contemplated as within the present invention. Further, the wall-
15 penetrating elements can be provided by microbarbs, for example having a diameter in the range of about 0.005 inches to about 0.010 inches, but may be of any suitable diameter such as, but not limited to, about 0.0005 inches to about 0.10 inches. The lengths of
20 such microbarbs may be any suitable length, typically in the range of between about 0.010 inches and about 0.100 inches, but may be of any suitable length including but not limited to about 0.001 inches to about 0.50 inches. The microbarbs can comprise a
25 series of metallic wires or any other suitable material, or can be formed into a larger element by surface texturing techniques, such as ion texturing or EDM, or any other suitable method. The larger element can then be attached to the flexible material in any
30 suitable manner. The microbarbs can be shaped to clutch the wall of the vessel at the implant site, with

the shape including but not limited to a wedged shape where the tip of the wedge comes into contact with the vessel wall, or a curved or pointed or fish-hooked wire, or any other appropriate configuration.

5 [0034] It will also be understood that a combination of techniques can be used in the attachment of areas of the valve body to the vessel wall. Illustratively, the use of wall penetrating elements as discussed above can be made in combination with adhesive and/or tissue
10 welding techniques as described further herein.

 [0035] Figure 3 provides a perspective view of one illustrative percutaneous deployment device of the invention. Deployment device 31 generally includes an expandable frame 32 attached to an elongate member 34
15 such as a stylet, received within a luminal device such as a catheter 33. Distal tip 35 of elongate member 34 is designed to be non-damaging to vessels in which it is to be deployed. A first end of frame 32 is connected at or near distal tip 35 by struts 36, and a
20 second end of frame 32 is connected to member 34 at a more proximal location by struts 37. Frame 32 is shown in its expanded configuration, deployed by pushing the end of stylet 34 out of the end of catheter 33. Frame 32 of device 31 has wire or other frame elements
25 configured to selectively force lip 16 against the vessel wall in a path extending longitudinally along and at least partially circumferentially around the vessel wall, e.g. in a generally serpentine pattern. Frame 32 can be retracted back into catheter 33 by
30 pulling stylet 34 proximally, thus collapsing struts 37, frame 32 and struts 36 for receipt within catheter

33. The end opening of catheter 33 may be configured with a taper or other adaptation to facilitate collapse and receipt of these frame and strut elements, if desired. Additionally, in an alternate embodiment, proximal struts 37 can be attached to catheter 33, rather than stylet 34. In this fashion, frame 32 may reside externally of catheter 33 during the entire delivery and deployment operation. In this latter embodiment, where frame 32 is self-expanding, forcing the stylet 34 distally outward from the catheter will retain a collapsed frame configuration, and removing that force will allow frame 32 expansion. Where frame 32 is not self-expanding, it may be caused to expand by pulling stylet 34 proximally, and caused or allowed to regain a collapsed configuration by causing or allowing the stylet 34 to move distally.

[0036] With reference now to Figures 1-4 together, shown in Figure 4 is a vascular valve deployment system 41 having a stentless valve body 11 (see Fig. 1 or 2) received upon deployment system 31 as shown in Figure 3. In the illustrated system 41, valve body 11 is releasably attached to the frame 32 by a suture 38 wound through body 11 and around frame 32. Suture 38 extends into and through the lumen of catheter 32, such that a physician can pull and remove the suture 38 after deployment of the valve body 11 against the vessel wall. In this regard, other means for releasably retaining valve body 11 on frame 32 may also be used, including for example the use of tacky materials such as biocompatible polymers, e.g. a polyvinylpyrrolidone polymer. Suitable

polyvinylpyrrolidone polymers that provide tack are known and commercially available, and can be used in the present invention. Other biocompatible adhesives are also known and can be used to temporarily or
5 releasably secure lip 16 to frame 32.

[0037] Referring now to Figure 5, shown is another vascular valve deployment system 51 of the invention, including an alternative expandable element for deployment of the valve body. System 51 includes a
10 delivery device 52 including an outer sheath 53 and a delivery catheter 54 receivable therein. Delivery catheter 54 includes a relatively narrow section 55 underlying an inflatable balloon 57 expandable element, to facilitate receipt of the balloon 57, when deflated,
15 into the outer sheath 53. Delivery catheter 54 also includes a distal tip 56 adapted to be non-damaging to the vascular vessel in which it is used.

[0038] Balloon 57 in the illustrative device includes adaptations that allow it to selectively force the lip
20 16 or edge of valve body 11 (see e.g. Figures 1 and 2) against the vessel wall. In the illustrated embodiment 51, balloon 57 adopts a predetermined shape upon inflation, the shape including at least one edge 58 configured to follow the lip 16 or other edge of valve
25 body 11. A balloon that is partially or wholly non-compliant (e.g. having sufficient rigidity or stiffness, altogether or in appropriate areas, to inflate to the predetermined, regular shape) may be used for these purposes. In this manner, when balloon
30 57 is inflated, balloon edge 58 will force lip 16 against the vessel wall to secure the lip 16 to the

vessel wall. As discussed hereinabove, barbs may be used to facilitate this attachment. In the illustrated system 51, a biocompatible adhesive 51 is incorporated along lip 16 for these purposes. In this regard, in
5 certain forms of the invention, the biocompatible adhesive can be an activatable adhesive, such that once lip 16 is in position against the vessel wall, the adhesive can be activated to thereby attach the lip 16 to the vessel wall. For example, the adhesive can be
10 an energy-activated adhesive, such as an adhesive activated by electromagnetic radiation, heat, or other energy sources. Illustratively, the adhesive can be an ultraviolet-light curable adhesive that is activated to bond the lip 16 to the vessel wall upon impingement by
15 UV light. The UV light or other energy for activation of the adhesive can be provided by the delivery system itself by the incorporation of an appropriate energy source to deliver energy to the desired region(s), or can be applied using a separate probe or other
20 instrument delivered to the implantation site either through the same percutaneous access or a different percutaneous access. In certain forms of the invention, where the valve device is delivered upon a balloon, a light-curable adhesive can be utilized and
25 the balloon or adjacent regions of the delivery device can incorporate the light source, similar to that used in balloon devices currently used for photodynamic therapy.

[0039] Furthermore, in addition to the potential use
30 of an adhesive to selectively attach areas of the valve material to the vessel wall, known tissue welding

techniques can be used to attach those areas. As before, the energy can be provided by one or more sources built into the delivery structure, and/or can be provided by a probe delivered separately to the
5 implant site either through the same percutaneous access or a different percutaneous access.

[0040] Illustratively, tissue welding within the vascular vessel can be conducted using laser welding techniques. For example, CO₂, Nd:YAG, THC:YAG, Argon,
10 and near infrared diode lasers, can be used for these purposes. Such laser welds can also involve the use of substances to improve the weld strength (e.g. solders), including for example the application of proteins to the weld areas, including for instance fibrinogen,
15 fibrin, albumin, or the like, or by the use of dyes such as fluorescein, isothiocyanate, and indocyanine green, to enhance absorption of laser radiation at the site to be welded. Further in this regard, to improve the welding process, the areas of the valve body
20 material to be welded to the vessel wall can contain collagen fibrils having free ends, wherein the free ends having a melting temperature below that of intact collagen fibrils included other areas of the valve body material. To achieve this, using a collagenous valve
25 body material, the lip, edges or other desired areas of the flexible piece to be connected to the vessel wall can be treated with appropriate digestive or other agents to release collagen fibril free ends, and/or collagen fibers can be separately incorporated into
30 these areas.

[0041] Other forms of energy can be also used in welding processes and/or adhesive activation processes, including for example microwave energy, radio frequency energy, ultraviolet light energy, and others. In each case, appropriate probes can be used to deliver the energy and/or such energy sources can be encompassed within the delivery system and configured to deliver energy to the desired sites, bands, or regions of attachment of the valve body to the vessel wall. Also in each case, for adhesive or welding purposes, an appropriate energy absorbing material that absorbs energy within a predetermined range of wavelengths or types, may be applied to the valve body to facilitate attachment.

[0042] The flexible or otherwise movable material (e.g., 12, Figure 1) used in valve bodies of the invention is a biocompatible material, and is preferably a remodelable material. Suitable remodelable materials may be made from natural or synthetic polymers, and preferred materials comprise collagen. Thus, in general, the flexible material may comprise a material such as synthetic biocompatible polymers such as cellulose acetate, cellulose nitrate, silicone, polyethylene terephthalate, polyurethane, polyamide, polyester, polyorthoester, polyanhydride, polyether sulfone, polycarbonate, polypropylene, high molecular weight polyethylene, polytetrafluoroethylene, or mixtures or copolymers thereof; polylactic acid, polyglycolic acid or copolymers thereof, a polyanhydride, polycaprolactone, polyhydroxy-butyrates

valerate, polyhydroxyalkanoate, or another biodegradable polymer.

[0043] In certain embodiments of the invention, the flexible material 12 is comprised of a naturally
5 derived or synthetic collagenous material, and especially an extracellular matrix material. Suitable extracellular matrix materials include, for instance, submucosa (including for example small intestinal submucosa, stomach submucosa, urinary bladder
10 submucosa, or uterine submucosa), renal capsule membrane, dura mater, pericardium, serosa, peritoneum or basement membrane materials, including liver basement membrane. These layers may be isolated and used as intact natural sheet forms, or reconstituted
15 collagen layers including collagen derived from these materials or other collagenous materials may be used. For additional information as to submucosa materials useful in the present invention, and their isolation and treatment, reference can be made to U.S. Patent
20 Nos. 4,902,508, 5,554,389, 5,993,844, 6,206,931, and 6,099,567. Renal capsule tissue can also be obtained from warm blooded vertebrates, as described more particularly in copending United States patent application serial No. 10/186,150 filed June 28, 2002
25 and International Patent Application serial No. PCT/US02/20499 filed June 28, 2002, published January 9, 2003 as WO03002165. In addition, the flexible material employed in the invention may be provided as a single layer, or as a multilaminate structure. In this
30 regard, techniques for laminating ECM or other collagenous layers can include fusing, crosslinking,

bonding, suturing, or other suitable techniques. In certain aspects of the inventions, a multilaminate ECM or other collagenous structure can be used, wherein the attachment of adjacent layers is achieved at least in part using dehydrathermal bonding, for example induced by compressing or otherwise forcing layers against one another, and drying the layers. The drying can occur under heated conditions, under lyophilization conditions which may include freeze drying or evaporative cooling, under vacuum pressing conditions at room temperature or otherwise, and the like. Each of these may be combined with other techniques including chemical crosslinking and/or the use of suitable bonding agents such as glues or adhesives. As well, multilaminate structures, when used, can include layers of the same material, or of differing materials. Illustratively, the multilaminate structures can include at least two differing collagenous layers, e.g. in the case of laminating together two differing materials.

[0044] In certain embodiments of the invention, the material used in the construction of the valve bodies of the invention can have adaptations that cause the material to resist attachment or incorporation into the vessel wall where such would be undesirable. For example, moveable portions of the valve body such as leaflet areas can incorporate or be coated with materials that decrease the likelihood of attachment or incorporation into the vessel walls. Illustratively, the moveable portions of the valve body can be coated with a synthetic polymer, including biodegradable

synthetic polymers, over all or a portion of their exterior surfaces that will be exposed to contact to the vessel walls. Other areas of the moveable portions, including internal areas, could also bear such coatings. As well, the material in these areas can incorporate agents that improve resistant to attachment of incorporation into the vessel walls, including antiproliferative agents such as paclitaxel and other taxol derivatives, for example as disclosed in U.S. Patent Nos. 5,157,049 and 5,616,608.

[0045] Frame elements 32, struts 36, 37, stylets 34, barbs 17, hooks 24, and other components of all embodiments of the present invention may also be made with any suitable biocompatible material. These include for example metals such as nitinol or other shape-memory materials, or stainless steel, as well as resorbable or nonresorbable polymeric materials, including those discussed above.

[0046] With reference now to Figure 6, shown is another vascular valve deployment system 61 of the present invention. Deployment system 61 includes a delivery device 62 including an outer sheath 63 and a delivery catheter 64 receivable therein. Delivery catheter 64 includes an expandable member 65 such as an inflatable balloon (e.g. potentially similar to balloon 57 of Fig. 5), for delivery of a valve body 66 received thereon. Expandable member 65 is flanked by both a proximal occlusion element 67 and distal occlusion element 68. Occlusion elements 67 and 68 can be provided, for example, by occlusion balloons made of latex, silicone, or any other suitable material. Catheter 64 also

includes one or a plurality of distal perfusion opening(s) occurring distally of distal occlusion element 68, and one or a plurality of proximal perfusion opening(s) 70 occurring proximally of proximal occlusion element 67. In use, the system 61 can be introduced into a vascular vessel 71 such as a vein, and the occlusion elements 67 and 68 can be expanded to isolate the vein segment occurring therebetween, in order to facilitate the delivery and/or attachment of the valve 66. Illustratively, the occlusion elements 67 and 68 can be expanded prior to expansion of the expandable member 65, such that when the valve 66 is deployed against the adjacent vessel wall surfaces, those surfaces will be isolated from significant blood flow. This may facilitate effective attachment of the valve body 66 to the wall using the mechanical or structural wall penetrating elements, and/or adhesives, and/or other techniques described herein. After attachment of the valve body 66 to the vessel walls, the expandable member 65 and the occlusion elements 67 and 68 can be contracted (e.g. deflated in the case of balloons), and the catheter 64 withdrawn back into sheath 63, and the sheath/catheter system withdrawn from the patient leaving in place the deployed valve body 66. In addition, it should be noted that during the time in which the vessel segment is occluded, perfusion opening(s) 69 and 70 and their associated catheter lumen can allow for perfusion of blood through the occluded segment.

[0047] With reference now to Figures 7-10, illustrated are additional systems and methods for percutaneously

providing valves within vascular vessels. In particular, provided is a delivery system 80 including a valve body securement and delivery device 81, receivable within an outer catheter or sheath 82.

5 Device 81 includes adaptations for releasably securing flexible material for delivery percutaneously into a vascular vessel. Specifically, in the illustrated device, provided is a first tong including closely approximated wire elements 83 and 84, and a second tong

10 including closely approximated wire elements 85 and 86. The first and second tongs extend in paths corresponding to a desired path of attachment of flexible material to the vessel wall.

[0048] Referring now to Figure 8, illustrated is one

15 manner securing a valve-forming flexible material to a tong of delivery device 81. A sheet of flexible material 87 is positioned underneath the wire elements 83 and 84. The edges of the flexible material are then rolled inwardly (see arrows) and tucked in between wire

20 83 and wire 84. In this manner, the edges of the flexible material, in the desired attachment path, are received tightly between wire elements 83 and 84. In this regard, Figure 9 shows this arrangement in a cross-sectional view taken along line 9-9 of Figure 8

25 (only after tucking the edges of flexible material 87) and viewed in the direction of the arrows. It will be understood that to grip the flexible material 87, wires 83 and 84 in the tong are closely enough spaced and of a resiliency wherein they clamp and hold flexible

30 material 87 therebetween during delivery and securement to the vessel walls.

[0049] With reference to Figure 10, shown is an illustrative deployment of flexible material with system 80 to provide a valve within a vascular vessel 90. As shown, each tong of delivery device 81 supports a piece of flexible material (87, 87'), and upon advancement out of delivery sheath 82, the tongs move radially outward to compress portions of flexible material 87,87' against the vessel walls at least in the areas where attachment to the walls is desired. Although flexible material 87,87' can be provided by separate pieces of material, it may also be provided by a single piece of material. The flexible material 87,87' is then attached to the walls in the desired areas using any suitable means therefor. Illustratively, such means may include barbs, hooks, bonding agents, welding, staples, and any other mechanisms disclosed herein or otherwise appropriate. Illustrated in Figure 10 is a probe 91 advanced from a separate percutaneous access, which has an energy-delivering tip 92. Probe 91 is used to deliver energy to facilitate attachment of the flexible material 87,87' to the vessel walls, for example in the shaded region designated at 93. As discussed hereinabove, the energy may function to weld the flexible material to the vessel walls and/or to activate adhesives or other substances to facilitate attachment to the vessel walls.

[0050] After attachment of the flexible material 87,87' to the vessel walls, probe 91 and system 80 can be withdrawn from the patient, leaving in place flexible material 87,87' in a structure beneficially modifying

blood flow through the vessel by selectively permitting blood flow in a first direction and restricting blood flow in a second direction opposite the first direction. In this regard, optionally, to facilitate
5 release of the flexible material 87,87', the delivery device 81 can incorporate a mechanism that can be actuated by the attending physician to separate the wires 83 and 85, and 85 and 86, to release the flexible material. For example, wires 83 and 85 can be at least
10 partially retractable to cause such separation.

[0051] Figures 11-13 are illustrative of certain flexible material configurations and attachments for providing valve function in a vascular vessel. In particular, Figure 11 represents a top view of an
15 implanted or engrafted valve generally in a closed condition and including flexible material 87,87' forming leaflets that provide a valving function. These leaflets have free edges 88 and 89 that move toward and away from one another to close and open,
20 respectively, the valve orifice. As before, shaded areas 93 represent a bonded and/or welded attachment of areas of flexible material 87,87' to the wall of vessel 90. Figure 12 provides a similar view of an implanted valve, except wherein a plurality of mechanical
25 elements such as staples 94 is used to attach flexible material 87,87' to the vessel wall.

[0052] Figure 13 provides a side view that could be representative of the valves in either of Figure 11 or Figure 12, showing a potential attachment path (in
30 phantom) for the leaflet edges extending in a direction generally both longitudinally and circumferentially

around the vessel wall, thus providing two cusp-type leaflets within the vessel 90. It will be understood that these leaflet paths could be the site of attachment by any suitable means as discussed herein, including but not limited to mechanical elements, bonding, and/or welding.

[0053] Devices and systems of the invention are desirably adapted for deployment within the vascular system, and in particularly preferred embodiments, devices and systems of the invention are adapted for deployment within the venous system. Accordingly, preferred devices such as device 11 and the others illustrated are adapted as venous valves, for example for percutaneous implantation within veins of the legs or feet, to treat venous insufficiency. In this regard, the frameless nature of valves of the present invention is expected to provide advantages in venous valve function, for example in situations wherein valve function and blood flow is facilitated by adjacent muscle pumps, e.g. in the legs or feet. In these cases, the absence of any frame or support structure exerting substantial radial force upon the venous vessel will allow the vessel to collapse as in native function. As well, such frames or structures can in certain situations undesirably migrate into vessel walls, and/or cause or facilitate thrombus or embolism. The absence of such frames or structures will therefore eliminate these associated factors.

[0054] It will be understood that other valve body configurations are contemplated as being within the scope of the present invention. For example, valves

disclosed in published U.S. Patent Application Serial No. 777,091 filed February 5, 2001, published as 20010039450 on November 8, 2001, can be modified to provide valve devices and systems in accordance with
5 the present invention (including the removal of any stent or frame elements present in the prior-disclosed valves).

[0055] It will also be understood that although certain embodiments disclosed herein have deployment systems
10 that selectively force certain areas of the valve body material against the vessel wall, such is not necessary to broader aspects of the present invention. In particular, standard balloon or expandable devices can be used, and the flexible material of the valve body
15 appropriately configured and adaptations applied, so as to achieve the implantation of a functional valve. For example, force can be applied essentially uniformly to a larger area of flexible material, wherein only a portion (e.g. band) of the flexible material has
20 adaptations that facilitate its attachment to the vessel wall. For instance, attachment mechanisms such as hooks, barbs, or other wall penetrating elements, and/or adhesives or tissue-welding solders or chromophors, can be applied only to those areas for
25 which attachment is desired. Such adaptations can be used with the embodiments disclosed hereinabove and others within the scope of the present invention. As well, it is within the scope of the present invention to deliver and lodge a valve body within a vascular
30 vessel, withdraw the delivery system, and then in a separate, later operation, use percutaneous means as

described herein to attach the valve body to the vascular vessel to provide the permanent, implanted structure. Still further, portions of the valve body delivery system (e.g. devices with expandable elements
5 to force the valve body against the vessel walls) can be left indwelling for a period of time to allow secure attachment of the flexible material to the vessel walls, for example by tissue ingrowth in the case of flexible materials such as ECMS having remodelable
10 properties. After secure attachment, the delivery system element can then be withdrawn.

[0056] While the invention has been illustrated and described in detail in the drawings and foregoing description, the same is to be considered as
15 illustrative and not restrictive in character, it being understood that only the preferred embodiment has been shown and described and that all changes and modifications that come within the spirit of the invention are desired to be protected. In addition,
20 all publications cited herein are indicative of the abilities of those of ordinary skill in the art and are hereby incorporated by reference in their entirety as if individually incorporated by reference and fully set forth.

WHAT IS CLAIMED IS:

1. A percutaneous vascular valve, comprising:
a stentless vascular valve body having at least
5 one flexible member for restricting blood flow, the
flexible member having an edge for contacting a wall of
a vascular vessel;
said edge adapted to attach to said wall.
- 10 2. The valve of claim 1, wherein said edge
includes barbs.
3. The valve of claim 1 or 2, wherein said edge
includes an adhesive.
- 15 4. The valve of any of claims 1-3, wherein said
flexible member comprises a remodelable material.
5. The valve of any of claims 1-4, wherein said
20 flexible member comprises a collagenous material.
6. The valve of claim 5, wherein said
collagenous material comprises an extracellular matrix.
- 25 7. The valve of claim 6, wherein the
extracellular matrix comprises submucosa.
8. The valve of any of claims 1-7, wherein the
stentless vascular valve body comprises at least two
30 leaflets.

9. The valve of any of claims 1-8, wherein said edge is configured to extend longitudinally along and at least partially circumferentially around the vessel wall.

5

10. The valve of any of claims 1-9, wherein said edge is a reinforced edge.

11. The valve of claim 10, wherein said
10 reinforced edge has a thickness greater than a central portion of said flexible member.

12. A percutaneous vascular valve and delivery system, comprising:

15 a stentless vascular valve body having at least one flexible member for restricting blood flow, the flexible member having an edge for attachment to a wall of a vascular vessel;

a percutaneous deployment device, the deployment
20 device having an expandable element for selectively forcing said edge against the wall.

13. The valve and delivery system of claim 12,
wherein said edge has a plurality of structural
25 elements for attaching to said wall.

14. The valve and delivery system of claim 13,
wherein said structural elements include barbs.

30 15. The valve and delivery system of any of claims 12-14, wherein said edge includes an adhesive.

16. The valve and delivery system of any of claims 12-15, wherein said expandable element comprises a wire frame.

5

17. The valve and delivery system of any of claims 12-16, wherein said stentless valve body comprises a remodelable material.

10 18. The valve and delivery system of claim 17, wherein said remodelable material is collagenous.

15 19. The valve and delivery system of any of claims 12-18, wherein the stentless valve body is releasably attached to the expandable element.

20 20. The valve and delivery system of claim 19, wherein the stentless valve body is releasably attached to the expandable element with an adhesive.

21 21. The valve and delivery system of claim 19, wherein the stentless valve body is releasably attached to the expandable element with a removable component.

25 22. The valve and delivery system of claim 21, wherein the removable component comprises a removable suture.

30 23. The valve and delivery system of claim 19, wherein the stentless valve body is releasably attached

to the expandable element by an attachment adaptation on said body, said element, or both.

24. A medical device, comprising a valve of any
5 of claims 1-11, in combination with a percutaneous deployment device.

25. The medical device of claim 19, wherein said percutaneous deployment device has at least one
10 expandable element for forcing said edge of said valve against a vessel wall.

26. A method for modifying blood flow in a vascular vessel, the method comprising:
15 percutaneously delivering one or more pieces of flexible material to a site within a vascular vessel;
and
percutaneously attaching at least portions of said one or more pieces of flexible material to walls of the
20 vascular vessel so as to form a structure that selectively permits blood flow in a first direction and resists blood flow in a second direction.

27. The method of claim 26, wherein said flexible
25 material has remodelable properties.

28. The method of claim 26, wherein said flexible material contains collagen.

30 29. The method of claim 26, wherein said flexible material comprises an extracellular matrix material.

30. The method of claim 29, wherein said extracellular matrix material contains collagen.

5 31. The method of claim 30, wherein said extracellular matrix material comprises submucosa.

32. The method of claim 26, wherein said structure includes a valve having two or more leaflets.
10

33. The method of claim 26, wherein said flexible material comprises collagen, and wherein said percutaneously attaching includes delivering energy to facilitate attachment of said portions to the wall.
15

34. The method of claim 33, wherein said energy includes electromagnetic radiation.

35. The method of claim 34, wherein said energy is selected from microwave, radio frequency, laser, and ultraviolet light energy.
20

36. The method of claim 33, wherein an energy-absorbing substance is provided in contact with said portions, and wherein said energy activates the energy-absorbing substance to attach said portions to the wall.
25

37. The method of claim 33, wherein the energy welds said portions to the wall.
30

38. The method of claim 26, wherein said percutaneously delivering comprises deploying the flexible material from a lumen of a percutaneously advancable device.

5

39. The method of claim 38, wherein said percutaneously delivering comprises deploying a delivery structure from the lumen, the delivery structure including the flexible material releasably held to an expandable element.

10

40. The method of claim 39, wherein the expandable element includes a balloon.

15

41. The method of claim 38, wherein the expandable element includes a wire structure.

20





42. The method of claim 26, wherein said attaching includes attaching a band of said flexible material in a path extending at least partially longitudinally and at least partially circumferentially along the wall.

25

43. A percutaneous vascular valve, comprising:
a vascular valve body free of any support structure and having at least one movable member for restricting blood flow, the movable member having an edge for contacting a wall of a vascular vessel;
said edge adapted to attach to said wall.

30

1/9






FIG. 2




FIG. 3




FIG. 4





FIG. 6e



7/9





FIG. 9




FIG. 8







FIG. 10



INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/009971

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61F2/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	US 6 254 636 B1 (PEREDO MARIO OSVALDO VRANDECIC) 3 July 2001 (2001-07-03) the whole document	1,4-11, 43 12,17, 18,24,25
X Y	WO 00/64381 A (ST JUDE MEDICAL) 2 November 2000 (2000-11-02) the whole document	1,2, 5-11,43 13,14
X	WO 01/64137 A (FIGULLA HANS REINER ;DOERRER PEGGY (DE); HARNISCH GERD (DE); WEBER) 7 September 2001 (2001-09-07) page 1, line 15 - line 19; figure 1 page 2, line 31 -page 3, line 5 page 6, line 25 -page 7, line 8 --- -/--	1,2, 12-14, 24,25,43

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

30 July 2004

Date of mailing of the international search report

06/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Newman, B

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US2004/009971

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 364 905 B1 (CASAGRANDE IVAN ET AL) 2 April 2002 (2002-04-02)	1,3,43
Y	column 2, line 15 - line 28; claims 1,17; figure 1	15
Y	US 2002/138138 A1 (YANG JIBIN) 26 September 2002 (2002-09-26) page 3, paragraph 53 page 9, paragraph 102	12-15, 17,18, 24,25
A	US 2002/169456 A1 (QUIJANO RODOLFO C ET AL) 14 November 2002 (2002-11-14) page 2, paragraph 27	19-23

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/009971

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 26 - 42
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/009971

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6254636	B1	03-07-2001	AU 4709699 A	17-01-2000
			BR 9911565 A	18-09-2001
			CA 2335619 A1	06-01-2000
			CN 1304298 T	18-07-2001
			EP 1089675 A1	11-04-2001
			JP 2002519098 T	02-07-2002
			WO 0000107 A1	06-01-2000
			US 2002077698 A1	20-06-2002
			ZA 200007440 A	06-06-2001
WO 0064381	A	02-11-2000	BR 0010096 A	19-02-2002
			EP 1173116 A2	23-01-2002
			EP 1173117 A2	23-01-2002
			JP 2002541974 T	10-12-2002
			WO 0064381 A2	02-11-2000
			WO 0064382 A2	02-11-2000
			US 2003195497 A1	16-10-2003
			US 6589279 B1	08-07-2003
			US 6582419 B1	24-06-2003
			US 2004078074 A1	22-04-2004
			ZA 200108640 A	20-01-2003
WO 0164137	A	07-09-2001	DE 10010073 A1	27-09-2001
			WO 0164137 A1	07-09-2001
			EP 1259193 A1	27-11-2002
			JP 2003524504 T	19-08-2003
			US 2003149476 A1	07-08-2003
US 6364905	B1	02-04-2002	US 2002116053 A1	22-08-2002
US 2002138138	A1	26-09-2002	WO 02076348 A1	03-10-2002
			US 2003055495 A1	20-03-2003
US 2002169456	A1	14-11-2002	US 2004111096 A1	10-06-2004
			US 2004078072 A1	22-04-2004